Zenas Biopharma Announces Approved New Inducement Grants
Zenas BioPharma granted inducement stock options covering 300,000 shares to two newly hired employees on December 15, 2025, at...
FDA Approves Jascayd for Progressive Pulmonary Fibrosis
Boehringer Ingelheim has secured FDA approval for Jascayd (nerandomilast) tablets to treat progressive pulmonary fibrosis (PPF) in adults, the...
Centessa’s Latest OX2R Update & Q3 Financial Results
Centessa Pharmaceuticals reported positive Phase 2a results for its oral OX2R agonist, ORX750, across narcolepsy type 1, narcolepsy type...
Pharming Group Q3 2025: Surging Revenue & Profitability
Pharming Group posted a 30% year-over-year revenue increase to $97.3 million in Q3 2025 and lifted full-year guidance to...
Pharmacorp Announces C$15 Million Bought Deal Offering
Pharmacorp Rx has secured a C$15 million bought deal to fuel its pharmacy roll-up strategy, selling 35.7 million units...
Trethera’s Breakthrough: $2.7M Grant for KRAS Resistance
Trethera has secured a $2.7 million NIH Small Business Innovation Research grant to evaluate its first-in-class DCK inhibitor, TRE-515,...
Athira Pharma Secures Cancer Drug with $236 Million Funding
Athira Pharma has licensed global rights (excluding Asia and certain Middle Eastern countries) to lasofoxifene from Sermonix Pharmaceuticals, positioning...
Outlook Therapeutics Reports FY 2025 Financial Results
Outlook Therapeutics posted fiscal 2025 results with its first commercial revenue from Lytenava, an ophthalmic formulation of bevacizumab for...
Sai Life Sciences Releases 2024-25 Sustainability Report
Sai Life Sciences has published its 2024–25 sustainability report, aligning with GRI Universal Standards 2021 and SASB, and outlining...
BioSyent Announces Renewal of Normal Course Issuer Bid
BioSyent has received TSX Venture Exchange approval to launch a normal course issuer bid allowing the company to repurchase...